HRA00129-C004

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

Topoisomerase I inhibitor, c-MET-targeted antibody-drug conjugate

MET expression	Colorectal Cancer	MET expression	Colorectal Cancer	HRA00129-C004 Sensitive: D – Preclinical HRA00129-C004 Sensitive : D	HRA00129-C004 Sensitive: D – Preclinical HRA00129-C004 Sensitive : D
MET expression	Gastric Cancer	MET expression	Gastric Cancer	HRA00129-C004 Sensitive: D – Preclinical HRA00129-C004 Sensitive : D	HRA00129-C004 Sensitive: D – Preclinical HRA00129-C004 Sensitive : D
MET expression	Lung Cancer	MET expression	Lung Cancer	HRA00129-C004 Sensitive: D – Preclinical HRA00129-C004 Sensitive : D	HRA00129-C004 Sensitive: D – Preclinical HRA00129-C004 Sensitive : D

Associations
(3)